Buying this yen ETF for Jubak Picks to hedge market risk–and maybe gain 5% or so
Yesterday in a post "One consequence of change in Fed policy likely to be a weaker dollar" I noted that a number of Wall Street and big international banks have forecast a drop in the dollar as a result of the Fed's decision to back off on raising interest rates in...
Overnight optimism at end of government shutdown gives way after New York open to disappointing earnings
Disappointing earnings from Caterpillar (CAT) and an earnings warning from Nvidia (NVDA) sent stocks down this morning, negating overnight enthusiasm in Asian markets at the end of the partial shutdown of the U.S. government. The miss from Caterpillar took those...
Adding Incyte to my Special Report: 10 Best Buys for after the Bear–and to my Volatility Portfolio
The Biotech sector is a prototypical risk on/risk off asset class. Just look at the performance of Incyte if you'd like an example. The stock plunged to a low of $58.58 on December 24as investors and traders shunned risk--risk of a recession, risk of the U.S.-China...
Danaher gives upbeat guidance at JPMorgan healthcare conference
Danaher (DHR) upped its revenue guidance for the fourth quarter on January 8. The company is scheduled to report fourth quarter earnings on January 29. At the conference the company said that its core revenue growth for 2018 to date was 6%. Core operating margins were...Pulling the plug on any significant end of the year rally: Selling small cap Russell 2000 ETF
Going into December, I thought there was enough chance of a strong end of the year rally/ January effect rally to make taking a risk on small company stocks a reasonable call. Even though the entire market looked shaky in the longer term. (That is in 2019.) With the...
Incyte knocking on the door of a new upward trend after today’s 6% pop
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte's (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte's Jakafi in combination with...
Jubak Picks member Salesforce beats on earnings, raises guidance for 2019 and 2020
Salesforce (CRM) started today to the upside based on last night's earnings beat of 11 cents a share. Salesforce shares were up 4.57% as of noon New York time today. And then came the market-wide bounce after Fed chair Jerome Powell's speech suggesting that the...
Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher
It's been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That's likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of the American...Mixed news in Alibaba’s new Singles’ Day sales record
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Buy Salesforce My Newest Big Thing Stock for Jubak Picks Portfolio today
When I added Salesforce.com (CRM) as my third artificial intelligence pick in my Next Big Thing Special Report yesterday, I wrote that given the volatility in the general market "I think I'd like to see the stock hold the 200-day moving average or move above it before...
Autoliv shares move up as future outweighs past
Before the market open today, Autoliv (ALV) delivered disappointing earnings for the third quarter. But the stock still climbed on news that China is considering cutting the tax on car purchases to 5% from 10% in an effort to stimulate the country's auto market at a...Jim’s Stock Alerts
Download Jim’s eBook for Free
